On August 19, an independent monitoring board looked at data from 1,137 melanoma patients and told Moderna and Merck to stop the suspense: their personalized mRNA cancer vaccine, paired with Keytruda, had beaten Keytruda alone. Wall Street didn't wait for the fine print. Moderna's stock more than doubled that day — its best single session ever (Forbes).

Here's the number that actually matters, and it's older than this week's headline. In the Phase 2b run that got everyone here, a 157-patient trial cut the risk of cancer coming back or killing the patient by 44% versus the standard of care (BioPharma Dive). The Phase 3 result confirms that wasn't a fluke — at roughly seven times the patient count.

The catch, and it's a real one: the companies haven't released the Phase 3 efficacy figures yet. They told the world it worked and are saving the actual hazard ratios for a medical conference. So the market repriced a company on a press release. That's the story — and the thesis: a made-to-order cancer shot just crossed the hardest bar in drug development, and the details we still don't have are worth billions.

🧠 Why This Matters

Most vaccines teach your immune system to spot a virus. This one teaches it to spot your specific tumor. After surgeons remove a melanoma, scientists sequence it, hunt for the mutations that make those cancer cells look different from healthy ones, and build a custom mRNA recipe — up to 34 of these "neoantigen" targets per patient (Merck). Your cells read the recipe, flag the fingerprint, and your T-cells go hunting for any stray cancer cell left behind.

The reason this is a big deal isn't the melanoma. It's the platform. If you can turn a patient's own tumor into a personalized vaccine on a repeatable manufacturing line, melanoma is just the first door. That's why one Phase 3 readout moved a stock like a takeover rumor.

"This is the first Phase 3 study to show that intismeran, a treatment designed based on the unique mutational 'fingerprint' of a patient's own tumor, given in combination with pembrolizumab can reduce the risk of recurrence or death." — Professor Georgina Long, principal investigator (Merck)

📊 Deep Dive

The trial is called INTerpath-001. The drug, once known as mRNA-4157, now goes by intismeran autogene. Here's what's under the hood:

  • Patients: 1,137 people with completely resected Stage IIB–IV melanoma — the high-risk cases where the tumor is gone but the fear of return is not.
  • The regimen: intismeran at 1 mg every three weeks (up to 9 doses), layered on top of Keytruda at 400 mg (Merck).
  • What it hit: the primary endpoint (recurrence-free survival) and a key secondary endpoint (distant metastasis-free survival) — meaning fewer cancers came back, and fewer spread to distant organs.
  • Phase 2b precedent: 157 patients, a 44% reduction in recurrence-or-death risk over roughly three years (CNBC).
  • The reaction: Moderna shares more than doubled; Merck's rose too. Jefferies analyst Andrew Tsai floated "billions of dollars in sales from the vaccine in melanoma alone" (BioPharma Dive).

Notice what's missing from that list: the Phase 3 percentages. The monitoring board saw "statistically significant and clinically meaningful" improvement and greenlit the readout — but the companies are holding the exact numbers for a future medical meeting. You're looking at a $100-billion-plus swing in market value built on the word "significant."

⚠️ The Catch

Start with the obvious: topline is not the same as approved. No hazard ratios, no p-values, no FDA filing date. When those numbers arrive, they'll either justify the run-up or deflate it, and history is littered with "met endpoints" press releases that looked thinner in the full dataset.

Then there's the manufacturing problem. A one-size-fits-all pill rolls off a line by the million. A personalized vaccine has to be built one patient at a time — sequence the tumor, design up to 34 targets, synthesize the mRNA, ship it back — for every single person. That's a logistics puzzle and a cost question rolled into one, and neither company has said what a course will cost or how fast they can turn one around.

And the 44% headline figure? It came from 157 patients. That's a small deck to bet a franchise on, which is exactly why the Phase 3 mattered — and exactly why the still-hidden Phase 3 effect size is the number to wait for.

🎯 What Happens Next

Two clocks are ticking. The first is regulatory: expect the companies to take this data to the FDA, with the full efficacy numbers surfacing at an oncology conference before any approval. The second is the pipeline expansion — intismeran is already being tested in kidney, bladder, and non-small cell lung cancers (BioPharma Dive). If the melanoma win reads across to even one of those, the addressable market stops being a niche skin-cancer play and becomes something much larger.

For Moderna specifically, this is an identity shift. The company that became a household name on a COVID shot now has a credible second act that has nothing to do with a pandemic — and investors just told it so, in one trading session.

🧩 Bigger Picture

Follow the money and it points at Keytruda. That drug is Merck's roughly $29.5-billion-a-year engine, and its patent protection starts eroding around 2028 (BioPharma Dive). A personalized vaccine that only works bolted onto Keytruda is a rather elegant way to keep patients — and revenue — tethered to the franchise well past the cliff. The combination is the moat.

TD Cowen's Tyler Van Buren called it a "landmark moment." (BioPharma Dive)

Zoom out and the shape is familiar: the same mRNA technology that raced a vaccine to market in a year is now being pointed at the disease that scares people most. The COVID shot proved the delivery system works at planetary scale. Cancer is the harder, more personal test — one tumor, one recipe, one patient at a time.

The vaccine cleared the trial. Now Moderna and Merck have to clear the part they haven't shown you yet — and a doubled stock price is already daring them to.

Sources